LumiraDx Ltd
NASDAQ:LMDX
Intrinsic Value
LumiraDX Ltd. engages in the provision of next-generation POC diagnostic company, which focuses on transforming community-based healthcare by providing critical diagnostic information to healthcare pr... [ Read More ]
The intrinsic value of one LMDX stock under the Base Case scenario is 0.02 USD. Compared to the current market price of 0.016 USD, LumiraDx Ltd is Undervalued by 22%.
Valuation Backtest
LumiraDx Ltd
Run backtest to discover the historical profit from buying and selling LMDX stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
LumiraDx Ltd
Current Assets | 175.3m |
Cash & Short-Term Investments | 25.3m |
Receivables | 64.8m |
Other Current Assets | 85.2m |
Non-Current Assets | 165.5m |
Long-Term Investments | 11.5m |
PP&E | 120.9m |
Intangibles | 32.3m |
Other Non-Current Assets | 800k |
Current Liabilities | 89m |
Accounts Payable | 66m |
Other Current Liabilities | 23m |
Non-Current Liabilities | 466.4m |
Long-Term Debt | 393.9m |
Other Non-Current Liabilities | 72.5m |
Earnings Waterfall
LumiraDx Ltd
Revenue
|
126.5m
USD
|
Cost of Revenue
|
-228.4m
USD
|
Gross Profit
|
-101.9m
USD
|
Operating Expenses
|
-203.2m
USD
|
Operating Income
|
-305.1m
USD
|
Other Expenses
|
-32.9m
USD
|
Net Income
|
-338m
USD
|
Free Cash Flow Analysis
LumiraDx Ltd
LMDX Profitability Score
Profitability Due Diligence
LumiraDx Ltd's profitability score is 34/100. The higher the profitability score, the more profitable the company is.
Score
LumiraDx Ltd's profitability score is 34/100. The higher the profitability score, the more profitable the company is.
LMDX Solvency Score
Solvency Due Diligence
LumiraDx Ltd's solvency score is 58/100. The higher the solvency score, the more solvent the company is.
Score
LumiraDx Ltd's solvency score is 58/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
LMDX Price Targets Summary
LumiraDx Ltd
Shareholder Return
LMDX Price
LumiraDx Ltd
Average Annual Return | -48.87% |
Standard Deviation of Annual Returns | 58.43% |
Max Drawdown | -100% |
Market Capitalization | 347.3m USD |
Shares Outstanding | 21 706 714 434 |
Percentage of Shares Shorted | 2.38% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
LumiraDX Ltd. engages in the provision of next-generation POC diagnostic company, which focuses on transforming community-based healthcare by providing critical diagnostic information to healthcare providers at the point of need, thereby enabling more informed medical decisions to improve health outcomes. The firm is focused on transforming community-based healthcare by providing critical diagnostic information to healthcare providers at the point of need. The firm has developed and launched LumiraDx Platform, a platform which is an integrated system comprised of a small, point of care (POC) instrument, microfluidic test strips, and secure digital connectivity. The firm has developed five diagnostic tests which includes SARS-CoV-2 antigen, SARS-CoV-2 antigen pool, SARS-CoV-2 antibody, International Normalized Ratio (INR) test, and D-Dimer test. The company has also developed two rapid COVID-19 reagent testing kits for use on open molecular systems, LumiraDx SARS-CoV-2 RNA STAR and SARS-CoV-2 RNA STAR. Its platform has a pipeline of approximately more than 30 tests in various stages of development for the community-based healthcare settings.
Contact
IPO
Employees
Officers
The intrinsic value of one LMDX stock under the Base Case scenario is 0.02 USD.
Compared to the current market price of 0.016 USD, LumiraDx Ltd is Undervalued by 22%.